Performing a multicentre study is usually not the ideal way to collect all of the data needed in the early stages of clinical drug development. That’s why CHDR developed the monocentre approach. With this approach, patients are brought to one central study site, where all of the necessary tests and measurements can be performed

Highlights

  • It is much easier to bring each patient to one facility, rather than conducting the trial at many different facilities
  • With our monocentre approach, we do not need to train doctors and nurses at other centres; instead, we can perform all of the tests here at CHDR, ensuring high consistency and quality.
  • Because monocentre studies are performed more quickly and with less variability, we can offer superior results at lower cost

More patients in the early phases of drug development

In recent years, we have e seen an increasing demand to obtain more information from early-stage studies. Sponsors want to know more than just whether their product is tolerated by patients; they want to actually see what it does in patients in the early phases of development. CHDR anticipated this demand, and we perform an increasing number of studies in patients. More importantly, the types of measurements we perform are high-tech. Many of these tests – for example, our NeuroCart® battery and our complex biomarkers – would be nearly impossible to perform in a multicentre setup. Therefore, we prefer to bring the patients to our facility, where we can collect all the measurements that are needed.

Contact CHDR